Investigating the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan province, Iran, in 2014-2015 (a before-after study)
More details
Hide details
Associated professor of cardiology, Farchian Hospital, Hamadan medical university, Hamadan, Iran
Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
Online publication date: 2018-07-15
Publication date: 2019-04-17
Electron J Gen Med 2019;16(2):em111
Use of statins reduces the risk of cardiovascular diseases, however, in some studies, contradicting results about statins especially atorvastatin with the risk of diabetes have been reported. The purpose of the present study, was to investigate the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan. 60 patients hospitalized in CCU, who were diagnosed with one type of infarction were included in this clinical trial performed as a before-after study. Demographic data were collected using a questionnaire. Before the study and 6 months after the start of the study, the parameters of lipid profile, HbA1c and GFR were measured. Atorvastatin with a dose of 80mg was given to the patients from the beginning of the study for 6 months. The results were analyzed using SPSS. The average age of the male and female patients was 63.83 and 61.11, respectively, which had an insignificant difference. 42 patients (70%) were male and the rest of them were female. Lipid profile results at the end of the study showed improved averages for the parameters, all of which were statistically significant compared to their values at the start of the study. The mean HbA1c increased from 6.19 to 6.43 (P=0.001), the mean fasting blood sugar increased from 103.66 to 110.51 (P=0.001), and the average glomerular filtration rate (GFR) decreased from 69.84 from the start of the study to 67.43 which was statistically significant (P=0.002). Systolic and diastolic blood pressure at the end of the study decreased compared to the start of the study where in systolic blood pressure, this decrease was significant (p=0.003). Based on the results of this study, although the use of atorvastatin reduces lipids, it may create the risk of hyperglycemia in these patients. However, a certain conclusion requires further studies.
Li JH, Joy SV, Haga SB, Orlando LA, Kraus WE, Ginsburg GS, et al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients. J Pers Med. 2014;4(2):147–62. https://doi.org/10.3390/jpm402... PMid:25563221 PMCid:PMC4263970.
The discovery and development of atorvastatin, a potent novel hypolipidemic agent. 2002:1–22.
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003 Jun;326(7404):1423. https://doi.org/10.1136/bmj.32... PMid:12829554 PMCid:PMC162260.
Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, et al. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014;9(12):e114519. https://doi.org/10.1371/journa... PMid:25531109 PMCid:PMC4273994.
Newsom LC. Primary Prevention of Atherosclerotic Cardiovascular Disease: Controversies and Clinical Considerations. Ann Pharmacother. 2014 Dec. PMid:25527102.
Bespalova ID, Riazantseva N V, Kaliuzhin V V, Murashev BI, Osikhov IA, Mediantsev IA. Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome. Kardiologiia. 2014;54(8):37–43. https://doi.org/10.18565/cardi... PMid:25464609.
David G, editor. Diabetic mellitus type 2. Greenspan’s basic & clinical endocrinology. 9th ed. 2011.
Xiang Y, Lan T, Lu Y. Using the Widely Available Blood Glucose Meter to Monitor Insulin and HbA1c. J Diabetes Sci Technol. 2014 Jul;8(4):855–8. https://doi.org/10.1177/193229... PMid:25562889 PMCid:PMC4764208.
Wang C-Y, Yu N-C, Sheu WH-H, Tsai S-T, Tai T-Y. Team care of type 2 diabetes mellitus in Taiwan. Diabetes Res ClinPract. 2014 Dec;106 Suppl:309–13. https://doi.org/10.1016/S0168-....
Bannon P, Lessard F, Lepage R, Joly JG, Dufresne L. Glycated hemoglobin in uremic patients as measured by affinity and ion-exchange chromatography. Clin Chem. 1984 Mar;30(3):485–6. PMid:6697506.
Zhou Y, Yuan Y, Cai RR, Huang Y, Xia WQ, Yang Y, et al. Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis. Expert OpinPharmacother. 2013;14(12):1575-84. https://doi.org/10.1517/146565... PMid:23826679.
Kakuda H, Matoba M, Nakatoh H, Nagao S, Takekoshi N. Effects of change in high-density lipoprotein cholesterol by statin switching on glucose metabolism and renal function in hypercholesterolemia. J ClinLipidol. 2015;9(5):709-15. https://doi.org/10.1016/j.jacl....
Van de Woestijne AP, van der Graaf Y, Westerink J, Nathoe HM, Visseren FLJ. Effect of Statin Therapy on Incident Type 2 Diabetes Mellitus in Patients With Clinically Manifest Vascular Disease. Am J Cardiol [Internet]? 2014;(0) Retrieved from http://www.sciencedirect.com/s....
Olotu BS, Shepherd MD, Novak S, Lawson KA, Wilson JP, Richards KM, et al. Use of Statins and the Risk of Incident Diabetes: A Retrospective Cohort Study. Am J Cardiovasc Drugs. 2016. https://doi.org/10.1007/s40256... PMid:27272032.
Ooba N, Tanaka S, Yasukawa Y, Yoshino N, Hayashi H, Hidaka S, et al. Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus. J Pharm Health Care Sci. 2016;2:8. https://doi.org/10.1186/s40780... PMid:26998342 PMCid:PMC4799528.
Simsek S, Schalkwijk CG, Wolffenbuttel BHR. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study. Diabet Med. 2012 May;29(5):628–31. https://doi.org/10.1111/j.1464... PMid:22151023.
Jensen MT, Andersen HU, Rossing P, Jensen JS. Statins are independently associated with increased HbA1c in type 1 diabetes--The Thousand & 1 Study. Diabetes Res Clin Pract. 2016;111:51-7. https://doi.org/10.1016/j.diab... PMid:26597211.
Huang CH, Huang YY, Hsu BR. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. J Diabetes Investig. 2016. https://doi.org/10.1111/jdi.12....
Pareek A, Chandurkar N, Thulaseedharan NK, Legha R, Agarwal M, Mathur SL, et al. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Curr Med Res Opin. 2015;31(11):2105-17. https://doi.org/10.1185/030079... PMid:26371518.
Li Q, Zhao YG, Wang Z, Jiang HP, Liu WB, Cao BF. Effects of First High-Dose Atorvastatin Loading in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Am J Ther. 2016. https://doi.org/10.1097/MJT.00... PMCid:PMC4885590.
Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014;57(12):2444-52. https://doi.org/10.1007/s00125... PMid:25245638.
Davis TM, Badshah I, Chubb SA, Davis WA. Dose-response relationship between statin therapy and glycaemia in community-based patients with type 2 diabetes: The Fremantle Diabetes Study. Diabetes ObesMetab. 2016.